0 0 -0.0047453071851511 -0.0047453071851511 -0.0047453071851511 -0.000545920295637057 -0.00852475538571377 -0.00894469407466514
Sign Up Today X
Thanks for submitting the form.
Stockreport

H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
Wainwright lowered its price target on Allogene Therapeutics, Inc. (NASDAQ:ALLO) to $11 from $12 while maintaining a Buy rating following the pricing of its previously announced $175M common stock offering. The firm said the recent share pullback appears “unwarranted” and views it as an attractive entry point. Meanwhile, Jefferies analyst Roger Song raised his price target to $10 from $6 and kept a Buy rating after interim data from the Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma exceeded expectations. The firm sees meaningful upside potential based on the early results. On April 12, 2026, Allogene reported data from a planned interim futility analysis of the ALPHA3 trial. At the protocol-defined cutoff—triggered when the 24th patient completed a Day 45 MRD assessment—58.3% of patients treated with cema-cel achieved minimal residual disease (MRD) negativity versus 16.7% in the observation arm, a 41.6 percenta [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
Wainwright lowered its price target on Allogene Therapeutics, Inc. (NASDAQ:ALLO) to $11 from $12 while maintaining a Buy rating following the pricing of its previously announced $175M common stock offering. The firm said the recent share pullback appears “unwarranted” and views it as an attractive entry point. Meanwhile, Jefferies analyst Roger Song raised his price target to $10 from $6 and kept a Buy rating after interim data from the Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma exceeded expectations. The firm sees meaningful upside potential based on the early results. On April 12, 2026, Allogene reported data from a planned interim futility analysis of the ALPHA3 trial. At the protocol-defined cutoff—triggered when the 24th patient completed a Day 45 MRD assessment—58.3% of patients treated with cema-cel achieved minimal residual disease (MRD) negativity versus 16.7% in the observation arm, a 41.6 percenta [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS